scholarly journals Study of incidence of allergic conjunctivitis in patients with allergic rhinitis

2021 ◽  
Vol 9 (10) ◽  
pp. 2930
Author(s):  
Sucheta Gupta ◽  
Vinod Gupta
Keyword(s):  
Primary Care ◽  
Allergic Rhinitis ◽  
Observational Study ◽  
Outpatient Clinic ◽  
Allergic Conjunctivitis ◽  
The Other ◽  
Jammu And Kashmir ◽  
Co Morbidity ◽  
Symptom Scores ◽  
Screening Questions

Background: Allergic conjunctivitis (AC) accounts for 15% of eye related consultations in primary care centers. AC is commonly manifesting as itchy or watering or red eye, comprising the symptoms of the total ocular symptom scores (TOSS). Recognition of AC is unreported even in patients with recognized AR (allergic rhinitis). Therefore, the objective of the present study was to identify the incidence of AC in patients with AR.Methods: This randomized observational study was conducted on 110 patients for a 6 month period from February to July 2019, having diagnosed AR and attending the outpatient clinic in CHC Chenani, district Udhampur, Jammu and Kashmir. The patients were directly questioned if they had AC, clarified by using standard screening questions of red, itchy and watery eyes and quantified by TOSS and were asked about indirect symptoms that may be attributable to AC.Results: Among the 110 patients, 50.9% of patients identified AC on direct questioning; additional symptoms were squint at 47.3% and blinking at 51.2%. Olopatadine, significantly reduced TOSS scores within 5 minutes of treatment and 80.9% showed improvement, which identified 39% silent sufferers of AC. A total of 90% AC subjects were identified through TOSS symptoms and totally 95.5%, detecting additional symptoms. The other co-morbidity that was associated with allergic conjunctivitis was allergic dermatitis.Conclusions: The screening questions could identify only about 56% of the patients with AC. Additional specific questioning and a therapeutic challenge in suspected patients can help identify patients who may benefit from treatment of AC. 

The effectiveness of sublingual immunotherapy for house dust mite-induced allergic rhinitis and its co-morbid conditions

Immunotherapy ◽  
2019 ◽  
Vol 11 (16) ◽  
pp. 1387-1397
Author(s):  
Alson Wai-ming Chan ◽  
Wing Pan Luk ◽  
Ling Hiu Fung ◽  
Tak Hong Lee
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Conjunctivitis ◽  
Adverse Reactions ◽  
Sublingual Immunotherapy ◽  
Controlled Study ◽  
Topical Steroids ◽  
Dust Mite ◽  
Symptom Scores ◽  
Rhinitis Symptom ◽  
Morbid Conditions

Aim: We investigated sublingual immunotherapy for mite-induced allergic rhinitis and its comorbid allergic conditions. Patients & methods: A prospective case-controlled study of 120 patients (case = 80, control = 40) over 12 months. Results: There was 53.6% reduction in total rhinitis symptom score (p < 0.0001), but not in controls (-7.3%, p = 0.99). The total symptom scores for concurrent asthma decreased from 17.79 to 8.8 (p < 0.0001); for allergic conjunctivitis from 20.89 to 10.0 (p = 0.0002); for atopic dermatitis from 46.40 to 29.38 (p = 0.0004) and 74.6% of patients weaned off nasal topical steroids. The treatment-related adverse reactions were mild and self-limiting. Conclusion: Though sublingual immunotherapy may be more expensive than conventional treatments, it was an adjunctive therapy that improved not only the outcomes for allergic rhinitis, but also its comorbid allergic conditions.

Comparative Study Between Preferential Consultations And Most Common Diagnoses

2016 ◽  
Vol 33 (S1) ◽  
pp. S451-S451
Author(s):  
C. Manso Bazús ◽  
J. Valdes Valdazo ◽  
E. Garcia Fernandez ◽  
L.T. Velilla Diez ◽  
J. Min Kim ◽  
...  
Keyword(s):  
Mental Health ◽  
Primary Care ◽  
Health Care ◽  
Observational Study ◽  
Affective Disorders ◽  
Primary Care Physicians ◽  
The Other ◽  
Health Care Burden ◽  
Competing Interest ◽  
The One

IntroductionTo the specialized attention arrives as preferred patients with minor diagnosis.ObjectiveWe do a relation between the type (normal/preferential) derivation of the first consultations and their corresponding diagnosis.MethodologyRetrospective observational study with data gathered during 3 months, which handle 2 variables: on the one hand, type of derivation and on the other, effected diagnosis.ResultsThe most frequent diagnosis found are adaptative disorders and affective disorders, corresponding to 45.45% and 9.1%, respectively of preferred leads.ConclusionsAlmost half of preferential queries (consultations) could be treated in first instance by primary care physicians releasing mental health care burden.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Clinical determinants of migraine preventive treatment: Contribution of SMILE, an observational survey of primary care migraine management in France

Cephalalgia ◽  
2010 ◽  
Vol 30 (10) ◽  
pp. 1207-1213 ◽  
Author(s):  
D Valade ◽  
M Lantéri-Minet ◽  
F Radat ◽  
C Mekies ◽  
C Lucas ◽  
...  
Keyword(s):  
Primary Care ◽  
Patient Satisfaction ◽  
Observational Study ◽  
Acute Treatment ◽  
Medication Overuse ◽  
Preventive Treatment ◽  
Preventive Therapy ◽  
The Other ◽  
Main Factors ◽  
Primary Care Medicine

Methods: SMILE was an observational study carried out in France among office-based general practitioners (GPs) and neurologists from November 2005 to July 2006 to assess the determinants of prescription of migraine preventive therapy in primary care medicine. A total of 1467 GPs and 83 neurologists were included, treating 5417 and 248 migraine sufferers, respectively. Results: The main factors leading physicians to deem a patient eligible for preventive treatment were perceived medication overuse and frequency of headaches, and secondarily, severity of headaches and functional impact. On the other hand, patient satisfaction with the acute treatment of attacks and triptan use, and secondarily, a long migraine history were found to influence patient eligibility negatively. Discussion/conclusion: Noticeably, psychiatric disorders (anxiety, stress) did not appear, aside from somatic factors, among the determinants that significantly influence physicians' judgment about the option of establishing a preventive treatment. However, they are important features of migraine condition and should be listed among the factors guiding choices about migraine preventive therapy.

scholarly journals Symptomatology and allergen types in patients presenting with allergic rhinitis

2012 ◽  
Vol 18 (1) ◽  
pp. 30-35
Author(s):  
R Nepali ◽  
B Sigdel ◽  
P Baniya
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Conjunctivitis ◽  
Care Center ◽  
Tertiary Care ◽  
Chief Complaint ◽  
Age Group ◽  
Tertiary Care Center ◽  
Co Morbidity ◽  
Males And Females ◽  
Global Health Problem

Allergic rhinitis, despite its complex patho-physiology, is a global health problem with the increasing prevalence. The current study which was conducted at one of the tertiary care center in the country comprised of 548 diagnosed cases of allergic rhinitis and thus treated during the period extending from January 2010 to June 2011. In the study, males and females were almost equally distributed, constituting the ratio of 1:0.9. Among them, the patients from 20 –29 year of age group was the most commonly affected (38.1%). In our study most of the patients were housewives (30.3%) and the house dusts mites (76.3%), was the most common etiological factors. Majority of the patients presented with sneezing (86.7%) as the chief complaint. Of the total subjects, 18.6% presented with co-morbidity of allergic conjunctivitis and 8.9% with that of sinusitis. DOI: http://dx.doi.org/10.3329/bjo.v18i1.10411  Bangladesh J Otorhinolaryngol 2012; 18(1): 30-35

scholarly journals EFFICACY OF ASCHYOTANA IN THE MANAGEMENT OF VATAJA ABHISHYANDA (ALLERGIC CONJUNCTIVITIS): AN OBSERVATIONAL STUDY

AYUSHDHARA ◽  
2020 ◽  
pp. 2636-2642
Author(s):  
Manisha Rajput ◽  
Sukhdev Singh ◽  
Sanjeev Kumar Sharma ◽  
Yogitha Bali M.R
Keyword(s):  
Allergic Rhinitis ◽  
Observational Study ◽  
Random Sampling ◽  
Allergic Conjunctivitis ◽  
Age Groups ◽  
Himachal Pradesh ◽  
Burning Sensation ◽  
Eye Drops ◽  
Eligibility Criteria ◽  
The People

Background: Inflammation of the conjunctiva due to allergy is known as allergic conjunctiva. It is also seen in the people suffering from allergic rhinitis and is affected by all age groups at least once in their lifetime. But older population and children are more prone for allergic conjunctivitis. Objectives: To evaluate the effect of Aschyotana karma or the therapy with Bilvadi eye drops in the management of Vataja abhishyanda (allergic conjunctivitis). Design: This was an observational study with random sampling. Forty subjects who fulfilled the eligibility criteria were included for the study. Patients with complaints of Allergic Conjunctivitis were selected from OPD of Department of Shalakya Tantra (Netra-Roga), R.G.G.P.G. Ayu. Hospital Paprola, Himachal Pradesh. These patients were administered Bilvadi aschyotana 2 eye drops 4to 5 times for 15 days and were assessed for itching, redness, burning sensation and photophobia before the treatment, on the 3rd day, once in a week and after the treatment.  Results: Aschyotana with Bilvadi eye drops in Vataja abhishyanda provided significant relief in itching 70.09%, redness 41.7%, burning sensation 47.6% and photophobia 53.3%.  

scholarly journals Observational study of administering intranasal steroid sprays by healthcare workers

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e037660 ◽  
Author(s):  
Marielle de Boer ◽  
Corine Rollema ◽  
Eric van Roon ◽  
Tjalling de Vries
Keyword(s):  
Allergic Rhinitis ◽  
General Practitioner ◽  
Observational Study ◽  
Outpatient Clinic ◽  
Healthcare Workers ◽  
Primary Outcome ◽  
Secondary Outcome ◽  
Optimal Distribution ◽  
Intranasal Corticosteroid ◽  
Know How

ObjectivesPatients with allergic rhinitis receive their information about administering intranasal corticosteroid sprays (INCS) from healthcare workers. Since the majority of patients does not administer these sprays correctly, we investigated whether healthcare workers know how to administer INCS.SettingsWe studied participants at their working place: pharmacy, outpatient clinic or general practitioner centre for emergencies.ParticipantsPharmacist assistants, general practitioners, paediatricians and ear nose throat doctors.DesignObservational study. All the participants demonstrated the administration technique with a spray device filled with water.Primary outcomeNumber of steps of administration of INCS based on the established INCS protocol.Secondary outcomeNumber of five steps are labelled essential to obtain optimal distribution of the medication.ResultsAmong the 75 participants, none performed all the steps correctly. The median of correctly performed steps in the protocol was 14 out of 29. A significantly better result was found among the pharmacist assistants. The essential steps were performed by 27 out of the 75 participants (36%).ConclusionThe majority of healthcare workers does not know how to administer INCS correctly. Patients could, therefore, receive incorrect and non-uniform instructions. The education of healthcare workers on how to administer INCS correctly may be an option for improvement.

Acrivastine in Seasonal Allergic Rhinitis: Two Randomized Crossover Studies to Evaluate Efficacy and Safety

1988 ◽  
Vol 16 (6) ◽  
pp. 413-419 ◽  
Author(s):  
T. G. Gibbs ◽  
K. Irander ◽  
O. P. Salo
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Dosage Regimen ◽  
The Other ◽  
Efficacy And Safety ◽  
Adverse Experiences ◽  
Crossover Studies ◽  
Symptom Scores ◽  
Equal Efficacy ◽  
Better Than

In two randomized crossover studies, the antihistamine, acrivastine, was evaluated for the treatment of seasonal allergic rhinitis. One study on 31 patients found both 4 and 8 mg acrivastine given three times daily to be significantly better than placebo for alleviating hay fever. There were no significant differences in symptom scores between the two doses, although more patients (63%) favoured 8 mg acrivastine over the 4 mg dose (46%) or placebo (35%). The other study found the higher dosage regimen to be similar in efficacy to 1 mg clemastine given three times daily. Both dosages were significantly better than placebo for reducing symptom scores in all 18 evaluable patients. The incidence of adverse experiences was low in both studies; there being no dose-related effects of acrivastine. In the second study, drowsiness, probably or possibly treatment related, occurred on seven occasions during clemastine treatment and once with acrivastine. These studies indicate that 8 mg acrivastine given three times daily is both well tolerated and of equal efficacy to clemastine for the treatment of seasonal allergic rhinitis.

Sign in / Sign up

Export Citation Format

Share Document